Search in:

Advanced search

Expert Review of Anticancer Therapy Volume 14, 2014 - Issue 1

Submit an article Journal homepage

363

Views

CrossRef citations to date

Altmetric

Reviews

Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer

Przemysław HolkoCentrum HTA, Krakow, Poland

Paweł KawalecDrug Management Department, Institute of Public Health, Jagiellonian University, Krakow, PolandCorrespondence[email protected]

Pages 63-73 | Published online: 10 Jan 2014

Cite this article
https://doi.org/10.1586/14737140.2014.856270
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300 (2010).
PubMed Web of Science ®Google Scholar
Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results. J. Urol. 160, 2428–2434 (1999).
Google Scholar
Eastham JA, Scardino PT. Radical prostatectomy for clinical stage T1 and T2 prostate cancer. In: Comprehensive Textbook of Genitourinary Oncology (2nd Edition). Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FM, Linehan WM (Eds). Lipincott Williams & Wilkins, Philadelphia, PA, USA, 722–738 (2000).
Google Scholar
Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J. Urol. 152, 1831–1836 (1994).
PubMed Web of Science ®Google Scholar
Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
PubMed Web of Science ®Google Scholar
Sartor AO. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J. Hematol. Oncol. 4, 18 (2011).
PubMedGoogle Scholar
Prostate Cancer: Principles and Practice (1st Edition). Kantoff PW, Carrol PR, D'Amico AV (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA (2002).
Google Scholar
Kawalec P, Paszulewicz A, Holko P, Pilc A. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Arch. Med. Sci. 8(5), 767–775 (2012).
PubMed Web of Science ®Google Scholar
Botrel TE, Clark O, Pompeo AC et al.Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis. Int. Braz. J. Urol. 38(6), 717–727 (2012).
PubMedGoogle Scholar
Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP. Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial. J. Clin. Oncol. 31(Suppl. 8), 74 (2013).
Google Scholar
Longo DL. New therapies for castration-resistant prostate cancer. N. Engl. J. Med. 363, 479–481 (2010).
PubMed Web of Science ®Google Scholar
Peppercorn J, Armstrong A, Zaas DW, George D. Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer. Urol. Oncol. 31(7), 1079–1084 (2013).
PubMedGoogle Scholar
Di Lorenzo G, Ferro M, Buonerba C. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. BJU Int. 110(2 Pt 2), E99–E104 (2012).
PubMedGoogle Scholar
Chambers JD, Neumann PJ. Listening to provenge - What a costly cancer treatment says about future medicare policy. N. Engl. J. Med. 364, 1687–1689 (2011).
PubMed Web of Science ®Google Scholar
Simoens S. Pharmaco-economic aspects of sipuleucel-T. Hum. Vaccin. Immunother. 8(4), 506–508 (2012).
PubMed Web of Science ®Google Scholar
Jönsson B, Wilking N. Cancer vaccines and immunotherapeutics: challenges for pricing, reimbursement and market access. Hum. Vaccin. Immunother. 8(9), 1360–1363 (2012).
PubMed Web of Science ®Google Scholar
Bahl A, Bellmunt J, Oudard S. Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies. BJU Int. 109, 14–19 (2012).
PubMedGoogle Scholar
Climent MA, Piulats JM, Sánchez-Hernández A et al.Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. Crit. Rev. Oncol. Hematol. 83, 341–352 (2012).
PubMedGoogle Scholar
Bitting RL, Armstrong AJ, George DJ. Management options in advanced prostate cancer: What is the role for sipuleucel-T. Clin. Med. Insights Oncol. 5, 325–332 (2011).
PubMedGoogle Scholar
Basch EM, Somerfield MR, Beer TM et al.American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J. Clin. Oncol. 25, 5313–5318 (2007).
PubMed Web of Science ®Google Scholar
Park KT. Perspectives on cost-effective medicine and the use of cost-effectiveness analyses. J. Pediatr. Gastroenterol. Nutr. 54, 2–3 (2012).
PubMedGoogle Scholar
Cost-Effectiveness in Health and Medicine (1st Edition). Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, New York, USA (1996).
Google Scholar
Naimark DMJ, Bott M, Krahn M. The half-cycle correction explained: Two alternative pedagogical approaches. Med. Decis. Making 28, 706–712 (2008).
PubMed Web of Science ®Google Scholar
Bremner KE, Chong CA, Tomlinson G, Alibhai SM, Krahn MD. A review and meta-analysis of prostate cancer utilities. Med. Decis. Making 27, 288–298 (2007).
PubMed Web of Science ®Google Scholar
Alemayehu B, Buysman E, Parry D, Becker L, Nathan F. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J. Med. Econ. 13, 351–361 (2010).
PubMedGoogle Scholar
Beer TM, Schellhammer PF, Corman JM et al. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. Urology 82(2), 410–415 (2013).
PubMed Web of Science ®Google Scholar
Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Tan-Torres Edejer T, Baltussen R, Adam T et al. (Eds). World Health Organization, Geneva, Switzerland (2003).
Google Scholar
Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 81(6), 1297–1302 (2013).
PubMed Web of Science ®Google Scholar
Schecter CB. Cost effectiveness in context. J. Clin. Oncol. 25, 609–610 (2007).
PubMedGoogle Scholar
Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146, 473–481 (1992).
PubMed Web of Science ®Google Scholar
Gomella L, Nabhan C, DeVries T, Whitmore J, Frohlich M, George D. 683 Estimating the overall survival benefit of sipuleucel-T in the impact trial accounting for crossover treatment in control subjects with autologous immunotherapy generated from cyropreserved cells. J. Urol. 187(4), e278–e279 (2012).
PubMedGoogle Scholar
Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer. J. Natl Cancer Inst. 104(4), 273–279 (2012).
PubMed Web of Science ®Google Scholar
Collins R, Fenwick E, Trowman R et al.A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technol. Assess. 11, iii–;iv; xv–xviii; 1–179 (2007).
Google Scholar
Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J. Natl Cancer Inst. 102(2), 82–88 (2010).
PubMed Web of Science ®Google Scholar
Kearns B, Lloyd Jones M, Stevenson M, Littlewood C. Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal. Pharmacoeconomics 31(6), 479–488 (2013).
PubMedGoogle Scholar
Zhong L, Pon V, Srinivas S et al.Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis. PLoS ONE 8(5), e64275 (2013).
PubMed Web of Science ®Google Scholar
Seal BS, Asche CV, Puto K, Allen PD. Efficacy, patient-reported outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (MPC): a systematic literature review. Value Health 16(5), 872–890 (2013).
PubMedGoogle Scholar
Hao Y, Evans C, Hwang S. PCN105 Recent advances in the treatment of metastatic castration resistant prostate cancer: impacton health related quality of life. Value Health 16(3), A146–147 (2013).
Google Scholar

Websites

US Food and Drug Administration: Summary Basis for Regulatory Action - Provenge, April 29, 2010. www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM213114.pdf
Google Scholar
Zhen B, Gupta G. FDA Statistical Review and Evaluation: Sipuleucel-T. www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM214543.pdf
Google Scholar
National Comprehensive Cancer Network: The NCCN clinical practice guidelines in oncology prostate cancer, 2011. www.nccn.org
Google Scholar
US Department of Labor Bureau of Labor Statistic: Consumer Price Index. All Urban Consumers – (CPI-U) 1913-2012. www.usinflationcalculator.com/inflation/consumer-price-index-and-annual-percent-changes-from-1913-to-2008/
Google Scholar
International Monetary Fund: United States. Gross domestic product per capita, current prices, World Economic Outlook Database, April 2012. www.imf.org/external/pubs/ft/weo/2012/01/weodata/weorept.aspx?sy=2012&ey=2012&scsm=1&ssd=1&sort=country&ds=.&br=1&c=111&s=NGDPDPC&grp=0&a=&pr.x=51&pr.y=15
Google Scholar
ClinicalTrials.gov identifier: NCT01306890. http://clinicaltrials.gov/show/NCT01306890
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer

References

Websites

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer

References

Websites

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date